메인메뉴 바로가기 본문내용 바로가기

의약품 부작용신고 및 피해구제 상담 : 1644-6223 / 14-3330

첨단바이오 포커스

국민의 안전과 건강을 지키는 한국의약품안전관리원

홈 > 알림마당 > 뉴스레터 > 첨단바이오 포커스

인쇄
게시글 보기
제목 첨단바이오 포커스 제7호
등록자 hyj0117 등록일 2021-07-02 조회수 2086

















Reference

1. 보건복지부 홈페이지 Available from: https://www.mohw.go.kr/react/al/sal0301vw.jsp?PAR_MENU_ID=04&MENU_ID=0403&page=1&CONT_SEQ=365961

2. 보건복지부 홈페이지 Available from: http://www.mohw.go.kr/react/al/sal0301vw.jsp?PAR_MENU_ID=04&MENU_ID=0403&page=1&CONT_SEQ=365827

3. “SUPPLEMENT APPROVAL” US FDA Accessed May 7, 2021 Available from: https://www.fda.gov/media/148386/download4. 

4. “SUPPLEMENT APPROVAL” US FDA Accessed June 11, 2021 Available from: https://www.fda.gov/media/150087/download

5. “HCT/P Inspection Information” US FDA Accessed May 21, 2021 Available from: https://www.fda.gov/vaccines-blood-biologics/compliance-actions-biologics/hctp-inspection-information

6. 반은미, 장동진, 권택현, 김애리. 미국 및 유럽의 의약품 GMP 실사 동향 연구. 약학회지 2019:63(1):15-23 

7. “Important Patient and Consumer Information About Regenerative Medicine Therapies” US FDA Accessed June 3, 2021 Available from: https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/important-patient-and-consumer-information-about-regenerative-medicine-therapies

8. “Committee for Advanced Therapies (CAT): work-plan-Apr” EMA. Accessed May. 5, 2021 Available from: https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-related-documents-advanced-therapies-april-2021_en.pdf

9. “Dacogen” EMA. Accessed Apr. 30, 2021 Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/dacogen

10. “Evoltra” EMA. Accessed May. 4, 2021 Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/evoltra

11. “Aldurazyme” EMA. Accessed May. 19, 2021 Available from: 

https://www.ema.europa.eu/en/medicines/human/EPAR/aldurazyme

12. “Orphan designations-eu3202365” EMA. Accessed May. 19. 2021 

Available from: https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3202365

13. “Orphan designations-eu3202366” EMA. Accessed May. 26. 2021 

Available from: https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3202366

14. “Orphan designations-eu3202378” EMA. Accessed May. 27. 2021 

Available from: https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3202378

15. “Orphan designations-eu3202380” EMA. Accessed May. 27. 2021 

Available from: https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3202380

16. Japan takes step forward towards treating hereditary deafness” Biospectrum. Accessed May. 31, 2021 

Available from: https://www.biospectrumasia.com/news/50/18263/japan-takes-step-forward-towards-treating-hereditary-deafness.html

17. Shen, C. et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. J. Am. Med. Assoc. https://doi.org/10.1001/jama.2020.4783 (2020). 

18. Gautret, P. et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int. J. Antimicrob. Agents https://doi.org/10.1016/j.ijantimicag.2020.105949 (2020).

19. Wu, J. et al. Early antiviral treatment contributes to alleviate the severity and improve the prognosis of patients with novel coronavirus disease (COVID-19). J. Intern. Med. https://doi.org/10.1111/joim.13063 (2020).

20. Deng, Y. et al. Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 (COVID-19) in Wuhan, China: a retrospective study. Chin. Med. J. (Engl.) https://doi.org/10.1097/CM9.0000000000000824 (2020).

21. Chen, T. et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. Br. Med. J. 368, m1091 (2020).

22. Qin, C. et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin. Infect. Dis. https://doi.org/10.1093/cid/ciaa248 (2020).

23. Guan, W. J. et al. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2002032 (2020).

24. Wu, C. et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern. Med. https://doi.org/10.1001/jamainternmed.2020.0994 (2020).

25. HASAN, Syed Shahzad, et al. Mortality in COVID-19 patients with acute respiratory distress syndrome and corticosteroids use: a systematic review and meta-analysis. Expert review of respiratory medicine, 2020, 14.11: 1149-1163.

26.Wang, M. et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 30, 269–271 (2020).

27. Sun, Z. et al. Potent neutralization of SARS-CoV-2 by human antibody heavychain variable domains isolated from a large library with a new stable scaffold. MAbs 12, 1778435 (2020).

28. Krasnodembskaya, A. et al. Antibacterial effect of human mesenchymal stem cells is mediated in part from secretion of the antimicrobial peptide LL-37. Stem Cells 28, 2229–2238 (2010).

29. Ryan, J. M., Barry, F. P., Murphy, J. M. & Mahon, B. P. Mesenchymal stem cells avoid allogeneic rejection. J. Inflamm. 2, 8 (2005).

30. DURAND, Nisha; MALLEA, Jorge; ZUBAIR, Abba C. Insights into the use of mesenchymal stem cells in COVID-19 mediated acute respiratory failure. npj Regenerative Medicine, 2020, 5.1: 1-9.

31. Meisel, R. et al. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 103, 4619–4621 (2004).

32. Hong, J. W. et al. Immune tolerance of human dental pulp-derived mesenchymal stem cells mediated by CD4(+)CD25(+)FoxP3(+) regulatory T-Cells and induced by TGF-beta1 and IL-10. Yonsei Med. J. 58, 1031–1039 (2017).

33. Lu, Y. et al. Human gingiva-derived mesenchymal stem cells alleviate inflammatory bowel disease via IL-10 signalling-dependent modulation of immune cells. Scand. J. Immunol. 90, e12751 (2019).

34. Zhu, H. et al. Therapeutic effects of human umbilical cord-derived mesenchymal stem cells in acute lung injury mice. Sci. Rep. 7, 39889 (2017).

35. Zhang, Z. H. et al. Mesenchymal stem cells increase expression of heme oxygenase-1 leading to anti-inflammatory activity in treatment of acute liver failure. Stem Cell Res. Ther. 8, 70 (2017).

36. Lee, H. J., Kim, S. N., Jeon, M. S., Yi, T. & Song, S. U. ICOSL expression in human bone marrow-derived mesenchymal stem cells promotes induction of regulatory T cells. Sci. Rep. 7, 44486 (2017).

37. Cells4Life Available from: https://cells4life.com/2020/03/coronavirus-stem-cell-therapy

38. South China Morning Post Available from: 

https://www.scmp.com/news/china/society/article/3052495/coronavirus-far-more-likely-sars-bond-human-cells-scientists-say.

39. Clinicaltrials.gov Available from: 

https://clinicaltrials.gov/ct2/show/NCT04333368?term=umbilical+cord+stem+cells&cond=coronavirus&draw=2

40. China.org.cn Available from: http://www.china.org.cn/china/2020-03/07/content_75785868.htm

 

첨부파일
첨단바이오포커스 제7호 (21년 7월).pdf [12803721 byte]